In the past twenty years, mesothelioma cancer treatment has received lots of attention in both the press and in medical journals. The condition is a fairly unusual one, with only 2500 or so new instances identified each year in the U.S., but it is also a particularly deadly disease that has proven financially expensive for a number of large corporations due to thousands of legal actions brought by former workers and construction employees who were exposed to asbestos while on the job. The ailment includes large fees, both concerning money as well as in human lives.

Mesothelioma is a cancer of the mesothelium, a protective lining that covers quite a few organs within the body, particularly the lungs. Extended asbestos exposure, a fibrous mineral generally utilized in building for fire prevention and insulation, exposes the lungs to the tiny, razor-sharp fibers of the mineral. These fibers embed themselves within the system’s soft tissues and cancer generally results. The onset of mesothelioma might not come for many years following the exposure; the average delay between exposure and the start of the disease is approximately 30 years. That means that an impacted individual probably won’t contract the illness for a few decades after leaving a workplace where they were subjected to asbestos.

mesothelioma cancer treatment

The forecast for sufferers of malignant mesothelioma is poor, as the disease often leaves the lungs unable to function properly and frequently propagates to other organs of the body before it is properly identified. Initial symptoms of the disease look like those of more widespread and more quickly treated ailments, which usually allows the disease to spread even further before a proper medical diagnosis can be made.

Mesothelioma cancer therapies include surgical treatment to eliminate damaged tissues, though studies have shown that surgery has a tendency to extend the patients’ lives by no more than 12 months, at most.

Those whose disease is localized within the body could be suitable for radiation therapies which are often given as a follow-up to surgery in order to stop the disease from dispersing in the event surgery didn’t get rid of all of the cancerous tissue.

Chemotherapy has shown promise in a few tests for the treatment of mesothelioma. While chemotherapy can be uncomfortable, tests show longer survival rates among sufferers treated in this way compared to those who had surgery alone.

Immunotherapy, including the utilization of interleukin-2 remains in the early phases. To date, the outcome of such treatments are inconclusive.

The most important problem in discovering new mesothelioma therapies is the fact that asbestos cancer is a relatively rare disease. Because of this, there is not lots of funding towards finding new treatments for the disease. Furthermore, the relative scarcity of patients makes it hard to find people on which to test new treatment procedures.